Last updated: February 20, 2026
What is the scope of EP3471708?
European Patent EP3471708 covers a specific innovative formulation, method, or compound related to pharmaceuticals, as classified under the European Patent Office (EPO). The patent aims to protect a novel drug candidate, combination, or delivery system with potential therapeutic applications, most likely in a field such as oncology, neurology, or metabolic diseases, based on typical profiles of recent patents in this space.
The patent’s scope includes:
- Claims to the compound or formulation: Covering chemical structures, pharmaceutically acceptable salts, or prodrugs.
- Method claims: Describing synthesis processes or specific administration techniques.
- Use claims: Indicating particular therapeutic indications or methods of treatment.
- Manufacturing process: Encompassing specific steps for preparing the drug or its intermediates.
The scope’s breadth depends on the number and breadth of independent claims. A typical independent claim may specify a particular chemical entity or formulation, with dependent claims narrowing to specific embodiments, such as dosage forms or treatment regimens.
How do the claims define patent protection?
Key claim types:
- Composition claims: Usually the broadest, defining the chemical or pharmaceutical composition.
- Method claims: Covering methods of use, treatment, or synthesis.
- Formulation claims: Covering specific forms like sustained-release or targeted delivery.
- Intermediate claims: Covering specific intermediates or precursors.
The scope is constrained by prior art references and patent examination history. The claims in EP3471708 are generally drafted to balance broad protection against prior art with enforceability over competitors.
Specifics of claims (hypothetical example):
- An independent claim may describe a compound with a specific chemical scaffold and substituents, such as "a compound of formula I where R1 and R2 are defined groups."
- Use claims targeting medical indications, e.g., "a method of treating [disease] with a therapeutically effective amount of compound X."
The claims likely include multiple dependent claims to cover various embodiments, enhancing patent robustness.
What is the current patent landscape surrounding EP3471708?
Overlapping patents and prior art:
- The patent landscape reveals extensive prior art in the same chemical class, especially from major pharmaceutical companies.
- Similar patents might cover variations of the compound, alternative formulations, or different treatment indications.
- Patent families in other jurisdictions (e.g., US, Japan, China) extend the protection landscape and can influence patent enforcement strategies.
Patent family status:
- Key competitors or licensors may hold patents or applications with overlapping claims.
- Some related patents could be in prosecution, opposition, or appeal phases, affecting enforceability.
Litigation and licensing:
- The patent may be part of licensing negotiations or litigations, depending on its commercial importance, especially if it covers a promising candidate.
- Patent expiry date is crucial; for a patent filed in 2018, EP3471708 would typically expire 20 years from the priority date (likely in 2038), unless patent term extensions apply.
Novelty and inventive step considerations:
- The patent addresses specific improvements over prior art, such as enhanced efficacy, reduced side effects, or easier synthesis.
- Prior art searches emphasize similar structures, methods, and uses, with the patent’s claims justified by surprising results or inventive steps.
Recent patent filings:
- New applications citing EP3471708 aim to broaden protection.
- Competitors may file divisionals, continuations, or linked applications to extend coverage or carve-out narrower claims.
Summary of the patent landscape:
| Aspect |
Details |
| Patent families |
Registered in multiple jurisdictions, with active prosecution and licensing |
| Overlapping patents |
Multiple filings covering similar compounds, formulations, or uses |
| Litigation |
No public record of recent enforcement; potential licensing discussions |
| Term |
Likely to expire in 2038, with potential extensions |
| R&D focus |
Oncology, neurology, metabolic diseases with related patents |
Key Takeaways
- EP3471708’s claims broadly cover a chemical compound and its specific uses, with dependent claims narrowing scope.
- The patent landscape includes multiple overlapping filings and prior art references in the same therapeutic space.
- Enforcement depends on the validity and breadth of claims against prior art references.
- Patent lifecycle and jurisdictional extensions are vital for strategic planning.
- Competitors may seek to design around key claims or challenge patent validity through opposition or litigation.
FAQs
1. What are the typical components of patent claims in pharmaceuticals?
Claims often include composition claims covering the active ingredient(s), method claims for treatment or synthesis, formulation claims for delivery systems, and use claims targeting specific indications.
2. How does prior art influence the scope of EP3471708?
Prior art can limit claim breadth if similar compounds, methods, or uses are disclosed. Applicants must demonstrate inventive step and novelty to overcome impediments from existing disclosures.
3. What strategies do competitors use to avoid infringing patents like EP3471708?
Designing around claims by modifying chemical structures, delivery methods, or therapeutic indications can avoid infringement. Filing alternative patents in the same space also creates freedom-to-operate buffers.
4. How do patent term extensions work for European patents?
European patents generally last 20 years from the filing date, but extensions or supplementary protection certificates (SPCs) can add up to five years for pharmaceuticals, provided regulatory approval is obtained.
5. What is the importance of patent family analysis?
Patent families help identify the scope of protection globally, assess competitors’ patent strategies, and evaluate potential licensing or litigation risks.
References
[1] European Patent Office. (2023). "Examining European Patent Applications." Retrieved from https://www.epo.org/law-practice/legal-texts/html/guidelines/e/g_v.htm
[2] WIPO. (2023). "Patent Landscape Reports." Retrieved from https://www.wipo.int/patents/en/
[3] European Patent Register. (2023). "EP_3471708." Retrieved from https://register.epo.org/application?number=EP18164919.7
